Entia Biosciences Stock Performance
| ERGO Stock | USD 0.0001 0.00 0.00% |
The firm shows a Beta (market volatility) of -0.83, which means possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Entia Biosciences are expected to decrease at a much lower rate. During the bear market, Entia Biosciences is likely to outperform the market. At this point, Entia Biosciences has a negative expected return of -0.79%. Please make sure to confirm Entia Biosciences' treynor ratio and day median price , to decide if Entia Biosciences performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Entia Biosciences has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fragile performance in the last few months, the Stock's technical and fundamental indicators remain very healthy which may send shares a bit higher in March 2025. The recent disarray may also be a sign of long period up-swing for the firm investors. ...more
| Begin Period Cash Flow | 24.1 K | |
| Total Cashflows From Investing Activities | -7117.00 |
Entia |
Entia Biosciences Relative Risk vs. Return Landscape
If you would invest 0.02 in Entia Biosciences on November 2, 2024 and sell it today you would lose (0.01) from holding Entia Biosciences or give up 50.0% of portfolio value over 90 days. Entia Biosciences is currently does not generate positive expected returns and assumes 6.2994% risk (volatility on return distribution) over the 90 days horizon. In different words, 56% of pink sheets are less volatile than Entia, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Entia Biosciences Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Entia Biosciences' investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Entia Biosciences, and traders can use it to determine the average amount a Entia Biosciences' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.126
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ERGO |
Estimated Market Risk
| 6.3 actual daily | 56 56% of assets are less volatile |
Expected Return
| -0.79 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.13 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Entia Biosciences is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Entia Biosciences by adding Entia Biosciences to a well-diversified portfolio.
Entia Biosciences Fundamentals Growth
Entia Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Entia Biosciences, and Entia Biosciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Entia Pink Sheet performance.
| Return On Asset | -1.64 | |||
| Operating Margin | (4.40) % | |||
| Current Valuation | 235.63 K | |||
| Shares Outstanding | 33.66 M | |||
| Price To Earning | (0.50) X | |||
| Price To Sales | 0.89 X | |||
| Revenue | 265.47 K | |||
| EBITDA | (1.29 M) | |||
| Cash And Equivalents | 76.05 K | |||
| Debt To Equity | (1.57) % | |||
| Book Value Per Share | (0.07) X | |||
| Cash Flow From Operations | (715.1 K) | |||
| Earnings Per Share | (0.05) X | |||
| Total Asset | 439.14 K | |||
| Retained Earnings | (13.37 M) | |||
| Current Asset | 73 K | |||
| Current Liabilities | 1.71 M | |||
About Entia Biosciences Performance
By examining Entia Biosciences' fundamental ratios, stakeholders can obtain critical insights into Entia Biosciences' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Entia Biosciences is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Entia Biosciences, Inc. engages in the development, production, and distribution of dietary supplements, nutraceuticals, and medical foods products in the United States. Entia Biosciences, Inc. was founded in 2007 and is headquartered in Sherwood, Oregon. Total Nutraceutical operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 6 people.Things to note about Entia Biosciences performance evaluation
Checking the ongoing alerts about Entia Biosciences for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Entia Biosciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Entia Biosciences generated a negative expected return over the last 90 days | |
| Entia Biosciences has high historical volatility and very poor performance | |
| Entia Biosciences has some characteristics of a very speculative penny stock | |
| Entia Biosciences has a very high chance of going through financial distress in the upcoming years | |
| The company has a current ratio of 0.11, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Entia Biosciences until it has trouble settling it off, either with new capital or with free cash flow. So, Entia Biosciences' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Entia Biosciences sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Entia to invest in growth at high rates of return. When we think about Entia Biosciences' use of debt, we should always consider it together with cash and equity. | |
| Entia Biosciences reported the previous year's revenue of 265.47 K. Net Loss for the year was (1.4 M) with profit before overhead, payroll, taxes, and interest of 173.97 K. | |
| Entia Biosciences currently holds about 76.05 K in cash with (715.1 K) of positive cash flow from operations. |
- Analyzing Entia Biosciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Entia Biosciences' stock is overvalued or undervalued compared to its peers.
- Examining Entia Biosciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Entia Biosciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Entia Biosciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Entia Biosciences' pink sheet. These opinions can provide insight into Entia Biosciences' potential for growth and whether the stock is currently undervalued or overvalued.
Other Information on Investing in Entia Pink Sheet
Entia Biosciences financial ratios help investors to determine whether Entia Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Entia with respect to the benefits of owning Entia Biosciences security.